Q&A // CITED
PT-141 Questions, Answered from the Record
Direct answers, study-attributed, no dosing advice.
How does PT-141 compare to flibanserin and testosterone for women?
PT-141 acts on central melanocortin desire circuits; in female rats it selectively raised solicitational sexual behavior without affecting reflexive behavior or motor activity [2]. Reviews report good evidence for bremelanotide and flibanserin in premenopausal HSDD [8], while transdermal testosterone is used off-label in postmenopausal women — a different population [10].
Is PT-141 better than PDE-5 inhibitors for erectile dysfunction?
"Better" is not established; they differ in mechanism. PDE-5 inhibitors act peripherally on vascular smooth muscle for blood flow; PT-141 acts centrally on hypothalamic circuitry for desire/arousal [1][13]. PT-141 is not FDA-approved for ED; male data are early-phase and one older study is disputed [7].
What is PT-141?
PT-141 is bremelanotide, a synthetic cyclic heptapeptide analogue of alpha-MSH that activates central melanocortin receptors (MC4R/MC3R) [1]. It is FDA-approved for HSDD in premenopausal women; other uses are off-label or investigational [7].
What is PT-141 peptide?
The PT-141 peptide is bremelanotide — a ring of seven amino acids (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, ~1025 Da) [1]. It is a melanocortin receptor agonist that works in the brain, not on blood vessels [1].
What does the PT-141 peptide do?
It activates central melanocortin receptors (chiefly MC4R) in the hypothalamus, engaging dopaminergic pathways tied to sexual desire [1]. In trials it raised desire and lowered desire-related distress in premenopausal women with HSDD [3].
What is PT-141 used for?
Its one FDA-approved use is treating acquired, generalized HSDD (low sexual desire causing distress) in premenopausal women [7]. Every other use — men, postmenopausal women, performance — is off-label or investigational [7].
Is PT-141 the same as bremelanotide?
Yes. PT-141 is the development/research name; bremelanotide is the international nonproprietary name (INN) for the same melanocortin receptor agonist [1]. The approved injectable is bremelanotide [7].
What is bremelanotide?
Bremelanotide is the INN for PT-141: a synthetic cyclic heptapeptide melanocortin (MC3R/MC4R) agonist [1]. It was FDA-approved in 2019 for HSDD in premenopausal women [7].
How does PT-141 work?
By activating central melanocortin receptors (MC4R/MC3R) in hypothalamic circuits such as the medial preoptic area, it engages dopaminergic pathways governing sexual desire [1]. fMRI work showed it altered brain processing of erotic stimuli and raised desire for up to 24 hours [5].
What receptors does PT-141 act on?
Chiefly the melanocortin 4 receptor (MC4R), with secondary activity at MC3R — both central-nervous-system subtypes [1]. Peripheral MC1R activation underlies the hyperpigmentation reported with repeated frequent dosing [7].
Does PT-141 work through the brain or through blood flow?
The brain. PT-141 acts centrally on hypothalamic circuitry, evidenced by hypothalamic neuronal activation (increased c-Fos) and fMRI changes in brain processing of erotic stimuli [1][5]. It does not act on vascular smooth muscle like PDE-5 inhibitors [13].
What is a melanocortin receptor agonist?
A compound that activates melanocortin receptors — a family of five G-protein-coupled receptors (MC1R-MC5R) responding to peptides like alpha-MSH [1]. PT-141 is an agonist at the central MC3R/MC4R subtypes [1].
Does PT-141 increase testosterone?
No — a common misconception. PT-141 does not act via the HPG axis and does not directly raise testosterone; it works on central melanocortin desire circuits [7]. Its mechanism is neural, not hormonal.
How is PT-141 different from PDE-5 inhibitors?
Mechanism and target. PDE-5 inhibitors act peripherally on vascular smooth muscle to improve erectile blood flow; PT-141 acts centrally on hypothalamic neurotransmission governing desire [1][13]. Different organ, different effect.
What is the PT-141 dosage?
The US label specifies, for approved HSDD use in premenopausal women, 1.75 mg subcutaneous as-needed (max one dose/24h, no more than 8 doses/month), with a terminal half-life ~2.7 h [7]. This is a labeled figure, not a recommendation for any individual.
How much PT-141 should I take?
This site gives no personal dosing advice. The only documented figure is the approved label dose — 1.75 mg subcutaneous as-needed for HSDD in premenopausal women — quoted as documentation, not a recommendation [7]. Off-label use is not approved [7].
How much PT-141 to inject?
The label's approved figure is 1.75 mg subcutaneous as-needed for HSDD in premenopausal women, with a maximum of one dose per 24 hours [7]. That is documentation of the approved product, not an instruction; this site recommends no dose.
What is the PT-141 dosage for women?
The approved label dose for premenopausal women with HSDD is 1.75 mg subcutaneous as-needed [7]. Phase 2 dose-finding in women evaluated 0.75, 1.25, and 1.75 mg before 1.75 mg was selected [7]. Reported as trial/label figures, not advice.
How do you reconstitute PT-141?
The approved product is a prefilled single-dose subcutaneous injection per the US prescribing information, not a powder the patient reconstitutes [7]. Reconstitution of "research chemical" material is outside any approved procedure; this site provides no preparation instructions.
How do you take PT-141?
The approved bremelanotide product is given by subcutaneous injection, as needed, per the US label [7]. This is documentation of the approved route, not a recommendation; this site gives no administration instructions.
How often can you take PT-141?
The label limits the approved product to one dose per 24 hours and no more than 8 doses per month [7]. In the 52-week extension, sustained use showed no new safety signals but recurrent nausea (40.4%) [4]. Labeled limits, not a recommendation.
What is the approved bremelanotide dose?
1.75 mg subcutaneous as-needed for acquired, generalized HSDD in premenopausal women — the dose tested in the RECONNECT Phase 3 trials (n=1267), which met both coprimary endpoints (FSFI-desire +0.35, FSDS-DAO item 13 -0.33, both P<.001) [3][7].